cap-1

CAP-1 is an inhibitor of HIV-1 capsid formation.

Cap-dependent endonuclease-IN-1 is a highly potent, orally active cap-dependent endonuclease inhibitor with antiviral activity for studying influenza virus infection.

CAP-100 is a monoclonal antibody targeting CCR7. It neutralizes the ligand binding site and signaling of CCR7. This compound effectively inhibits migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples induced by CCR7. CAP-100 can mediate potent tumor cell killing through host immune mechanisms and exhibits favorable toxicity profiles in related hematopoietic cell subsets. It is involved in research on antitumor activity and diseases like chronic lymphocytic leukemia (CLL).

NLRP3-IN-51 (Compound 3q) is an effective activator of the cholinergic anti-inflammatory pathway (CAP). This compound demonstrates potential for treating gouty arthritis as it inhibits the production of IL-1β in THP-1 cells induced by monosodium urate (MSU). Furthermore, NLRP3-IN-51 suppresses the phosphorylation of NF-κBp65 triggered by MSU without impacting the self-cleavage and activation of NLRP3, pro-caspase 1, or the second messenger caspase-1. Therefore, the initial stage of NLRP3 inhibition by NLRP3-IN-51 occurs through the activation of CAP.

Suberoylanilide hydroxamic acid (SAHA) is a class I and class II histone deacetylase (HDAC) inhibitor that binds directly to the catalytic site of the enzyme thereby blocking substrate access. [1] coumarin-Suberoylanilide hydroxamic acid (c-SAHA) is a SAHA derivative where the anilino cap" group is replaced by 7-amino-4-methylcoumarin to produce a fluorescent probe that competitively binds HDAC. [2] The fluorescence excitation and emission maxima of free c-SAHA is 325 and 400 nm

1,2-Dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) is a biotinylated phospholipid. It has been used in PEGylated polyamidoamine-dendrimer-conjugated supported lipid bilayers (SLB) to isolate circulating tumor cells and tumor cell microembolis from patient-derived blood by antibody-coated microfluidics. [1] It has also been used as a component of SLBs to detect protein-ligand binding with ortho-conjugated Texas Red DHPE. [2] In addition, 1,2-dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) has been used in SLBs partitioned into nanowells to create DNA curtains, which can be used as a high-throughput tool for detection of protein-DNA interactions at the single molecule level.[3]

Methyl brevifolincarboxylate (Brevifolincarboxylic acid methyl ester) is a potent influenza virus PB2 cap-binding inhibitor, exhibiting inhibitory activity against influenza virus A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) with IC50s of 27.16 μM and 33.41 μM, respectively, and possessing anti-oxidant activity[1][2].

2',3'-O-Isopropylideneguanosine is an alkylated guanosine building block.1,2It has been used in the synthesis of ordered honeycomb microporous films and mRNA cap analogs. 1.Gao, Y.-F., Huang, Y.-J., Xu, S.-Y., et al.Ordered honeycomb microporous films from self-assembly of alkylated guanosine derivativesLangmuir27(6)2958-2964(2011) 2.Kore, A.R., Shanmugasundaram, M., and Vlassov, A.V.Synthesis and application of a new 2',3'-isopropylidene guanosine substituted cap analogBioorg. Med. Chem. Lett.18(17)4828-4832(2008)

7-Methylguanosine 5'-diphosphate (7-Methyl-GDP) sodium, a cap analog, is utilized in the synthesis of mRNA cap analogues[1].

Cap-dependent endonuclease-IN-26, a potent inhibitor of cap-dependent endonuclease (CEN) with an IC50 of 286 nM, exhibits significant antiviral activity against a broad spectrum of influenza A and B strains [1].

N7-Methylguanosine-5'-triphosphate-5'-adenosine (m7GpppA) diammonium, a dinucleotide cap analog, facilitates in vitro RNA transcription [1].

M7GpppApG is a trinucleotide mRNA 5' cap analog utilized for in vitro RNA synthesis [1].

3'Ome-m7GpppAmpG, a trinucleotide cap analogue with a locked nucleic acid (LNA) molecule, demonstrates notable translational efficiency. It serves as a promising tool in molecular biology, applicable in mRNA vaccines and transfection processes, including protein production, gene therapy, and anti-cancer immunization [1].

3'Ome-m7GpppAmpG ammonium, a trinucleotide Cap analogue with a locked nucleic acid (LNA) component, demonstrates substantial translational efficiency. It emerges as a promising tool in molecular biology, applicable in mRNA vaccines and transfection processes including protein production, gene therapy, and anti-cancer immunization [1].

M7GpppAmpG is a trinucleotide 5′ cap analog, exhibiting capping efficiencies of 90% for the produced RNAs [1].

m7GpppAmpG ammonium is a trinucleotide 5′ cap analog with capping efficiencies of 90% for RNAs obtained [1].

m7Gpppm6AmpG, a trinucleotide mRNA 5' cap analog, facilitates RNA synthesis in vitro [1].

M7Gpppm6AmpG ammonium, a trinucleotide mRNA 5' cap analog, facilitates in vitro RNA synthesis [1].

M7GpppGpG, a trinucleotide cap analogue and oligonucleotide, protects against premature degradation by 5′-exonucleases and facilitates pre-mRNA splicing, mRNA transport, and protein biosynthesis initiation by recruiting essential proteins [1].

m7GpppGmpG, a trinucleotide 5′ cap analog, exhibits capping efficiencies of 86% for the RNAs obtained [1].

M7GpppGmpG ammonium, a trinucleotide 5′ cap analog, exhibits an 86% capping efficiency for the produced RNAs [1].

m7GpppUmpG, an oligonucleotide and a trinucleotide cap analogue of M 7 GpppNpG, serves as a chemical tool for the production of RNA with either cap 0 or cap 1 structures [1].

m7GpppUpG, an oligonucleotide and a trinucleotide cap analogue (M 7 GpppNpG), serves as a chemical tool for the production of RNA with either cap 0 or cap 1 structures [1].

m7GpppCpG, an oligonucleotide functioning as an M7GpppNpG trinucleotide cap analogue, serves as a chemical tool for the synthesis of RNA with cap 0 or cap 1 structures [1].